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MicroalbuminuriaAbstract Background: Corticosteroids are the universally accepted ﬁrst line therapy for moderate
and severe immune thrombocytopenia (ITP).
Objectives: We investigated the effect of a short course prednisolone on serum cystatin C and the
appearance of microalbuminuria as markers for renal injury in a group of ITP children.
Methods: The study involved 33 (19 males, 14 females) newly diagnosed ITP children divided into
two groups; group I included 15 children with no or mild bleeding treated according to ‘‘watch and
wait’’ policy; group II included 18 children of moderate or severe bleeding treated by oral pred-
nisolone. Fifteen healthy, age and sex matched children were enrolled as a control group. Blood urea,
serum creatinine, estimated glomerular ﬁltration rate (eGFR) by Schwartz formula, serum cystatin C
(by ELISA) and urinary albumin concentration (by immunoturbidimetric assay) were determined.
Results: The baseline investigations were comparable in the three groups and were within the refer-
ence ranges. Corticosteroids of 12 mg/kg cumulative dose had induced signiﬁcant increments in
serum creatinine [from 0.62 ± 0.16 to 0.84 ± 0.12 mg/dL, p< 0.0001] cystatin C [from
750.83 ± 108.1 to 2300.55 ± 991.94 ng/ml, p< 0.0001] and decreased eGFR [from
116.69 ± 40.87 to 79.76 ± 24.48 ml/min/1.73 m2, p= 0.001] without change in urinary albumin
concentration or induction of microalbuminuria in paired analysis.
Conclusion: Although not accompanied by microalbuminuria, steroid induced cystatin C elevation
could be attributed in part to impaired GFR. Large population follow up studies are recommended
to investigate the reversibility of this effect.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Cystatin C, a13-kD protein, is a member of competitive
lysosomal cysteine protease inhibitors.1 Its serum level has
the potential to be an excellent surrogate marker of the
glomerular ﬁltration rate (GFR).2,3 This is attributed to its
40 S.M. Ragab et al.stable production rate from all nucleated cells (except in thy-
roid malfunction),4 free ﬁltration by the glomeruli and its com-
plete re-absorption by proximal tubular cells. So, its serum
concentration generally reﬂects the glomerular ﬁltration rate
more closely than creatinine,5 being highly sensitive to ‘‘pre-
clinical’’ kidney dysfunction.6
Microalbuminuria (MA) was delineated to describe the
appearance of small quantities of albumin, too little to detect
by standard methods, in urine samples.7 Urinary albumin
excretion is hypothesized to be a renal risk marker in the gen-
eral population.8 Microalbuminuria could also be regarded as
a manifestation of a diffuse endothelial (micro vascular) injury
including kidney, so it is considered as a marker of kidney
damage.9
Corticosteroids, frequently used as standard ﬁrst-line ther-
apy for moderate and severe primary immune thrombocytope-
nia (ITP) bleeder,10 had been suggested to inﬂuence cystatin C
serum level independently of glomerular function11–13 as well
as to induce microalbuminuria.14
In this study, we have investigated the inﬂuence of short
course corticosteroid therapy on both serum cystatin C level
and the occurrence of microalbuminuria in a group of primary
ITP children in relation to the ordinary renal functions.
Materials and methods
Subjects
This study was conducted upon 48 children; the patient group
included 33 newly diagnosed children of primary ITP and 15
healthy children who were enrolled as controls. ITP children
(19 males, 14 females) were recruited from the Hematology
unit, Pediatric Department, Menouﬁa University, Egypt.
Their ages ranged from 1.3 to 18 years (mean of
8.03 ± 4.55 years). Using the criterion of the International
Working Group of ITP deﬁned in 2009,15 primary ITP was
deﬁned as a platelet count less than 100 · 109/L in the absence
of other causes or disorders that may be associated with
thrombocytopenia in an otherwise healthy child with an other-
wise normal complete blood count and peripheral blood
smear. The study excluded those with hepato-splenomegaly,
lymphadenopathy, weight loss, fever, bone or joint pain, a
family history of low platelets or easy bruising, history of pla-
telet lowering drug intake, presence of an abnormal hemoglo-
bin level, white blood cell count, or white cell morphology.
Although the recent guidelines advocate against bone marrow
(BM) aspirate in a typical case of acute ITP,16 however, in our
unit, we prefer to perform a BM aspirate, as the follow up may
not be assured.
Based on Blanchette et al.17 children with marrow aspi-
rate other than normal to increased number of megakary-
ocytes with normal myeloid and erythroid elements were
excluded. Those with abnormal renal functions were also
excluded.
The bleeding severity was categorized using the scale of
Bolton-Maggs.18 Using this method, bleeding was categorized
as (1) none or mild; no bleeding at all or bruising, petechiae,
occasional mild epistaxis with very little or no interference with
daily living; (2) moderate; more severe skin manifestations
with some mucosal lesions and more troublesome epistaxis
or menorrhagia; or (3) severe; bleeding episodes (epistaxis,melena, menorrhagia, and/or intracranial hemorrhage) requir-
ing hospital admission and/or blood transfusions, that is,
symptoms interfering seriously with quality of life. According
to the guidelines,16,19 ITP children with mild or no bleeding
were treated according to expectant ‘‘watch and wait’’ policy
while moderate and severe bleeding necessitated therapy.
According to the severity and the need for steroid therapy,
the included patients were categorized into two groups:
Group (I): included 15 ITP children (9 males, 6 females) of
non or mild bleeding who did not need pharmacological ther-
apy but treated according to watchful observation. Their ages
ranged from 2.1 to 18 years (mean of 8.41 ± 4.63 years).
Group (II): included 18 ITP children (10 males, 8 females)
of moderate or severe bleeding who needed therapy. Their ages
ranged from 1.3 to 15 years (mean of 7.7. ± 4.59 years). For
these patients a course of oral prednisolone, 2 mg/kg/day
(maximum 60 mg/day), was given in divided doses for a max-
imum of 14 days. Prednisolone is reduced in a stepwise fashion
at 5- to 7-day intervals, irrespective of the platelet count and is
stopped at the end of 21–28 days, regardless of the response.20
The study involved 15 age and sex matched healthy children
who were enrolled as controls. They were 9 males and 6
females. Their ages ranged from 3 to 12 years (mean of
6.4 ± 3.29 years). They had normal hemogram and renal func-
tions. Children with family history of low platelets or easy
bruising were excluded.
The study was performed between March 2013 and April
2014. The legal guardians of the included children provided
an informed consent for study participation. Ethical approval
was granted by the ethics committee of Menouﬁa Faculty of
Medicine, Egypt before study beginning.
Methods
The study design
The study investigated the effect of short course steroids on
serum cystatin C and the occurrence of microalbuminuria in
a group of newly diagnosed ITP children who had bleeding
manifestations that necessitated therapy (group II) in com-
parison with another group of ITP children who were trea-
ted according to expectant ‘‘watch and wait’’ policy (group
I) as positive controls and also compared to matched
healthy children (control group) as negative controls. For
both, patient group I and the control group, the clinical
evaluation and the investigations were done once; at diagno-
sis for group I and at the study time for the healthy chil-
dren. A paired evaluation and investigations were done for
group II, at diagnosis (before starting steroids) and after
receiving cumulative dose of 12 mg/kg (about 360 mg pred-
nisolone/m2) (at day 7).
The clinical evaluation included:
1. Full history taking for the patients including; onset, course,
duration, fatigue and history of previous viral infections.
2. Thorough clinical examination including blood pressure
estimation, purpuric site number and distribution and
mucous membrane bleeding (to assess the severity) and
presence of organomegaly.
3. Anthropometric measurements including; weight in kilo-
grams (with light clothes), height in meters (without shoes)
and surface area calculated by nomogram.
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A. Complete blood count (CBC), with direct platelet count
using automated cell counter using AC920 Autocounter
after calibration.
B. Bone marrow aspirate for patients at diagnosis.
C. Renal function tests including, blood urea estimated by
the Berthelot method21 and serum creatinine concentra-
tion determined by the kinetic Jaffe’ method,22 using
Beckman Coulter AU480, Japan.
D. The estimated glomerular ﬁltration rate (eGFR) based
on the Schwartz formula was calculated from serum cre-
atinine (Sc) and body length (L, [cm]), as eGFR = k
L/Scr and gives an estimate in ml/min/1.73 m2. Where
k is a constant of proportionality that reﬂects the rela-
tionship between urinary creatinine excretion and units
of body size. The value of k varies as a function of age
and sex being 0.33 in preterm infants, 0.45 in full-term
infants, 0.55 in children and adolescent girls, and 0.70
in adolescent boys.23
E. Serum cystatin C determination:
Sample Collection and assay for serum cystatin C:
Venous blood was drawn by sterile vein puncture.
Samples were transferred into plain tubes, immediately
centrifuged for 10 min at 4000 rpm; sera were separated
then were stored at 20 C until analysis. Serum cys-
tatin C level was measured by the enzyme-linked
immunosorbent assay (ELISA) using Human cystatin
C kit (BioVendor Research and Diagnostic Products L
aboratornı´medicı´naa. European Union, Czech
Republic), according to the manufacturer’s protocols.
Results were obtained in ng/ml.
F. Determination of albumin in urine:Tabl
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was determined by immunoturbidimetric assay usinge 1 Comparison between ITP children and the controls according to
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ann–Whitney U test.ORG5MA Micro-albumin kit, supplied by
ORGENTEC Diagnostika GmbH (Mainz, Germany).
Results were obtained in lg/ml.Statistical analysis
Statistical analysis was performed using SPSS-20 (SPSS Inc.,
Chicago, IL, USA). Data were expressed in mean ± SD.
Continuous parametric variables were presented as
means ± SD while for categorical variables numbers (%) were
used. In statistical analyses, compatibility with normal distri-
bution was evaluated using Shapiro–Wilk normality test. The
difference between 2 groups was performed by student’s
t-test for parametric continuous variables and by Mann-
Whitney (U) test for non-parametric variables. For more than
2 groups, one way analysis of variance (ANOVA) test was used
for parametric data and the Kruskal–Wallis test was applied to
discriminate differences in non-parametric variables. For
paired analysis paired t test and Wilcoxon Signed Rank test
were used for parametric and non-parametric variables respec-
tively. A multivariate analysis (the multiple linear regression
analysis) test was used to study the power of certain risk. All
tests were two-tailed and p value < 0.05 was considered statis-
tically signiﬁcant.
Results
According to the used bleeding severity scale,18 14 out of the
included 33 ITP children (42.4%) had no bleeding, 1 (3%)
had mild bleeding, 16 (48.5%) had moderate bleeding and 2
(6%) had severe bleeding.
The patient group (total 33 ITP children) and the control
group were comparable in age, sex distribution, systolic and
diastolic blood pressure. ITP children at diagnosis had signif-
icant higher Eosinophils% compared to the controls. No sig-
niﬁcant difference was observed between ITP children atthe clinical and the laboratory investigations.
l group n= 15 Test p-Values
.3 1.24 0.22
) 0.025 0.87
± 8.55 1.37 0.17
7.97 1.1 0.27
0.78 1.31 0.19
0.27 1.81 0.08
.9 2.83* 0.51
.0 1.91* 0.06
0.59 3.62* <0.0001
0.77 2.93* 0.31
10.03 2.09* 0.08
9.40 0.7 0.48
.61 1.46 0.14
± 75.10 5.51* <0.0001
4.46 1.15* 0.25
0.13 1.93 0.059
29.27 0.78 0.44
± 119.05 1.34 0.18
4.9 0.14 0.89
R, estimated glomerular ﬁltration rate. Bold numerical values
Table 2 Comparison between the studied groups according to the clinical and the laboratory investigations.
The studied groups p-Values
Group I at
diagnosis
n= 15
Group II at
diagnosis
(pre-steroid)
n= 18
Group II
(post steroid)
n= 18
Control group
n= 15
p p1 p2 p3
Age (years) 8.41 ± 4.63 7.7.±4. 59 – 6.4 ± 3.29 0.43
Male; n (%) 9 (60) 10 (55.6) – 9 (60) 0.95
Systolic BP (mmHg) 110.33 ± 8.55 110 ± 9.7 110.83 ± 8.78 106.33 ± 8.55 0.4 0.87 0.15 0.18
Diastolic BP (mmHg) 70.67 ± 7.98 69.44 ± 9.98 71 ± 8.3 67 ± 7.97 0.5 0.87 0.16 0.03
Blood urea (mg/dL) 26.2 ± 2.28 22.1 ± 9.6 23.28 ± 7.25 21.80 ± 4.46 0.16* 0.66 0.57 0.27
Serum creatinine (mg/dL) 0.62 ± 0.17 0.62 ± 0.16 0.84 ± 0.12 0.53 ± 0.13 0.17 <0.0001 <0.0001 <0.0001
eGFR (ml/min/1.73 m2) 111.57 ± 29.38 116.69 ± 40.87 79.76 ± 24.48 122.62 ± 29.27 0.68 0.002 <0.0001 0.001
Serum cystatin C (ng/ml) 854.33 ± 211.51 750.83 ± 108.1 2300.55 ± 991.94 733 ± 119.06 0.22* <0.0001 <0.0001 <0.0001
Urinary albumin (lg/ml) 17.2 ± 3.89 16.83 ± 4.8 15.12 ± 6.26 17.2 ± 4.92 0.96 0.42 0.30 0.26
n, number; eGFR, estimated glomerular ﬁltration rate.
p for comparison between the 2 patient groups at diagnosis and the control group.
p1 for comparison between patient group II (post steroid) and patient group I (at diagnosis).
p2 for comparison between patient group II (post steroid) and the control group.
p3 for comparison between patient group II at diagnosis (pre-steroid) and the same group post steroid.
Bold numerical values indicate signiﬁcance.
* Kruskal–Wallis test.
Figure 2 Comparison of serum cystatin C level (ng/ml) in group
I ITP children, group II ITP children (pre-steroids) and controls
compared to group II ITP children (post-steroids).
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serum creatinine, eGFR, serum cystatin C levels or urinary
albumin concentration (p> 0.05) (Table 1).
The serum cystatin C level ranged between 535 and
1200 ng/ml in the total patient group, for group I the range
was from 540 to 1200 ng/ml. Pretreatment cystatin C in group
II ranged between 535 and 915, while the post treatment level
ranged between 1310 and 4750 ng/ml. This range for the con-
trol group was from 500 to 915 ng/ml. The ranges of urinary
albumin were 8–24, 9–23 and 6–23 lg/ml in the total patient
group, patient group I and the healthy controls respectively.
Pretreatment urinary albumin in group II ranged between 8
and 24 lg/ml while the post treatment level ranged between
5 and 23 lg/ml.
Both patient groups of ITP at diagnosis had no signiﬁcant
difference in any of the evaluated clinical parameters or the
investigations in comparison with each other or with the con-
trol group. Compared to patient group I (ITP did not require
therapy) and to the controls, patient group II (after steroid
therapy) had signiﬁcant higher serum creatinine and cystatin
C levels and signiﬁcant lower eGFR without signiﬁcantFigure 1 Comparison of serum creatinine level (mg/dl) in group
I ITP children, group II ITP children (pre-steroids) and controls
compared to group II ITP children (post-steroids).difference in blood pressure, blood urea or urinary albumin.
Moreover, in these patients, steroid therapy induced a signiﬁ-
cant increase in diastolic blood pressure (p= 0.029) (Table 2),Figure 3 Comparison of the eGFR (ml/min/1.73 m2) in group I
ITP children, group Ii ITP children (pre-steroids) and controls
compared to group II ITP children (post-steroids).
Table 3 Multivariate logistic regression analysis for indepen-
dent predictors of eGFR among group II ITP children after
steroid therapy (n= 18).
SE t p-Values Standardized
b
Blood urea (mg/dL) 0.81 0.19 0.85 0.03
Serum creatinine (mg/dL) 25.47 3.87 <0.0001 0.61
Serum cystatin C (ng/ml) 0.01 0.81 0.42 0.15
Urinary albumin (lg/ml) 0.79 1.03 0.31 0.14
Bold numerical values indicate signiﬁcance.
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a signiﬁcant decrease in eGFR (p= 0.001) (Table 2 and
Figs. 1–3 respectively), without any changes in blood urea or
urinary albumin compared with their levels before steroid ther-
apy (Table 2). The multiple linear regression analysis showed
that serum creatinine was the only signiﬁcant predictor of
eGFR among ITP children group II after corticosteroid
therapy (Table 3).
Discussion
ITP is one of the most common primary hematologic disorders
encountered by pediatricians.24
Mild eosinophilia can be observed in these patients.17 This
was evident in this study, where the studied ITP children had
signiﬁcant higher eosinophil (%) compared to the healthy
children.
The major goal for treatment of ITP is to provide a safe
platelet count that prevents major bleeding rather than correct-
ing the platelet count to normal level. The majority of children
with newly diagnosed ITP lack signiﬁcant bleeding symptoms
and may be managed without therapy.10,16,19 Once the decision
to treat a patient with ITP has been made, and provided the
patient’s situation is not life-threatening, corticosteroids are
the standard ﬁrst-line therapy.10
Hypertension is one of the common steroid induced
complications.25
In this study, short course of oral prednisolone, had
induced signiﬁcant rise in diastolic blood pressure.
The major side effect of the corticosteroids on renal func-
tion remains controversial.
While chronic corticosteroid therapy results in decreased
muscle mass and decreased urinary creatinine excretion, sug-
gesting that creatinine production may be reduced secondary
to the muscle wasting of prolonged corticosteroid administra-
tion,26 steroid pulsed dose was responsible for transient reduc-
tion of GFR both in kidney homograft recipients and normal
subjects. Popovtzer et al.27 as well as in patients with severe
nephrotic syndrome as reported by Takanobu et al.28 who
had suggested that sodium and water retention during MP
pulse therapy resulted in interstitial edema and acute renal fail-
ure. Methylprednisolone (MP) pulse therapy also induced
GFR reduction in patients with collagen disorders without
renal involvement (nephritis).29
Cystatin C is a fascinating marker of GFR that bears cer-
tain advantages over the most widely used surrogate marker
of GFR; serum creatinine. There is high-level evidence that it
has a superior diagnostic sensitivity for the detection of mildlyimpaired GFR.2 This is because of its independence from
height, gender, age, and muscle mass unlike serum creatinine.30
However, corticosteroids, may adversely affect the reliability
of the cystatin C assay as an estimate of glomerular function.12
Steroid induced cystatin C elevation was reported in previ-
ous studies in different disease categories.11,13,31–33
Investigating such inﬂuence, in this study, both serum cre-
atinine and cystatin C levels of ITP children at diagnosis
including the pretreatment levels of the treated group (patient
group II) were within the reference ranges with no signiﬁcant
difference compared to the healthy children. Steroid therapy
with a cumulative dose of 12 mg/kg (about 360 mg/m2) oral
prednisolone had induced increase of both serum creatinine
[from 0.62 ± 0.16 to 0.84 ± 0.12 mg/dL (p< 0.0001)]
and serum cystatin C [from 750.83 ± 108.1 to
2300.55 ± 991.94 ng/ml (p< 0.0001)], with accompanying
signiﬁcant reduction in the eGFR [from 116.69 ± 40.87 to
79.76 ± 24.48 ml/min/1.73 m2 (p= 0.001)] in the paired com-
parisons. Post steroid serum creatinine and cystatin C levels
were also signiﬁcantly higher compared to their levels in the
non treated group and the healthy children.
In accordance with these results, Manetti et al.34 had
reported a rapid (24–48 h) increase of serum cystatin C as well
as creatinine concentrations after administration of high dose
of methylprednisolone (15 mg/kg body weight) in severe
Graves ophthalmopathy patients.
Moreover, in the only previous study upon ITP children,
Bardi et al.35 had reported a signiﬁcant rise of serum cystatin
C level after 3 days of corticosteroid (cumulative dose of
300 mg/m2 of 6-methylprednisolone) compared to the pre-
treatment level which was within the reference range but with-
out concurrent signiﬁcant change in serum creatinine or the
creatinine clearance based on the Counahan formula conclud-
ing that serum cystatin C is a more sensitive method than
serum creatinine or creatinine based methods for GFR estima-
tion in patients under corticosteroid medication.
On the other hand, other researchers reported absence of
such inﬂuence.36,37
The difference in the obtained results in different studies
may be related to the different steroid doses.
The mechanism/s underpinning serum cystatin C modiﬁca-
tions in patients treated with high dose of methylprednisolone
is admittedly not clear. Whether steroid induced cystatin C ele-
vation is due to intrinsic increased production or a decreased
elimination by glomerular ﬁltration due to impaired renal
function or related to otherwise mechanism is still not clear.
In vitro studies had suggested a promoter mediated glucocor-
ticoid increase in transcription of the cystatin C with a dose
dependent increase in dexamethasone-induced cystatin C pro-
duction in HeLa cells.38 The results of this work could support
what was reported that steroid induced cystatin C elevation
does not preclude the use of cystatin C in detecting impaired
renal function.32,35,39
Microalbuminuria is indicative of glomerular basement
membrane damage and may be reﬂective of vascular and
endothelial injury.40 Its importance as an independent predic-
tor of progressive renal disease was realized in previous
studies.41,42
It has been reported that corticosteroid administration
causes urinary albumin excretion in rats, although the underly-
ing mechanism is not known.43
44 S.M. Ragab et al.In this study, we investigated, for the ﬁrst time, the effect of
short course steroid therapy on the urinary albumin concentra-
tion in ITP children for the possible occurrence of microalbu-
minuria to study another aspect of steroid induced
nephrotoxicity namely the vascular toxicity. In untimed
urinary collections, urinary albumin concentration values of
3–30 mg/dL (30–300 lg/ml) generally are regarded as fulﬁlling
the deﬁnition of MA.44
Urinary albumin concentration in urine samples of ITP
children at diagnosis ranged between 8 and 24 lg/ml so, no
one had microalbuminuria at diagnosis. Steroids did not
induce signiﬁcant change in the urinary albumin concentration
or appearance in micro-albuminuria in any of the treated
children.
Actually, little data are available about the effect of gluco-
corticoid upon urinary albumin concentration.
In a retrospective cross-sectional analysis of 7010 patients
of different illnesses treated with corticosteroids, Monster
et al.14 study revealed that long term corticosteroid use was
associated with microalbuminuria. This association seems to
be present only in users of a combination of systemic and
non-systemic corticosteroids and in subjects with more than
one prescription for a corticosteroid per year. However, they
could not prove if this association was due to adverse effects
of corticosteroids themselves or to the effects of the underlying
disease.
Urinary albumin excretion has been described in subjects
with Cushing’s syndrome, that disappeared after removal of
their pituitary or adrenal tumor. Thus, it could be supposed that
corticosteroids through some unknown mechanism cause uri-
nary albumin loss, which is reversible upon discontinuation.45
In fact, absence of steroid induced microalbuminuria in our
studied ITP children may be related to its short course.
Among our ITP children group II after corticosteroid ther-
apy, the multiple linear regression analysis showed that serum
creatinine was the only signiﬁcant predictor of eGFR without
signiﬁcant effect of serum cystatin C. Again, this supports the
hypothesis that corticosteroid administration, may inﬂuence
the reliability of cystatin C assay for glomerular function
estimation.12
To summarize, the results of this study, conﬁrmed the ster-
oid induced cystatin C elevation without observable effect on
appearance of microalbuminuria.
Conclusions
Although not accompanied by microalbuminuria, the parallel
elevation of both serum creatinine and cystatin C in this study
could suggest a binary etiology of steroid induced cystatin C
raise namely; reduced excretion due to impaired GFR and
increased production. So, ITP children under short course of
prednisolone are at risk of renal toxicity that could be detected
by serum creatinine and creatinine based eGFR as well as by
cystatin C elevation without risk of microalbuminuria. Large
population, multicenter and follow up studies are highly rec-
ommended to afﬁrm our results and to clarify the reversibility
or not of this effect.
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